Vendor Directory

AI patient billing and revenue cycle platform focused on the patient responsibility portion of provider revenue, which the company notes has risen from roughly 5 percent of provider revenue in 2010 to about 20 percent today and is projected toward 30 percent by decade end. Billie is the AI billing agent, engaging patients across chat, text, email, and voice to answer billing questions, explain what is owed, and take payment, with the company stating it handles the majority of cases and staff step in for exceptions. The platform covers intelligent statements, personalized outreach, payment plans, card on file, autopay, and refunds, plus an eligibility and benefits agent. Positioning is deliberately complementary rather than displacing: the company frames the EHR as the system of record and itself as the system of action on top of it. Integrated with more than 20 leading EHRs via API or FHIR, with a bidirectional Epic integration listed in Connection Hub on the Epic Showroom as of July 2026. Reported footprint is more than 3,000 healthcare facilities with over $1 billion in patient payments processed. Customer reported results include collections increases in the 75 to 300 percent range and average days to collect as low as 12.6. Holds HIPAA, SOC 2 Type 2, PCI DSS, and HITRUST i1 compliance. Backed by Sapphire Ventures and Y Combinator; CEO and co-founder Levon Brutyan.

Voice AI care management for health plans and at risk providers, originating in vocal biomarker research for detecting depression and anxiety and now productized as Sage, an AI care manager. The distinguishing technical claim is the Empathy Engine, patented vocal biomarker technology trained on millions of live clinical patient calls, which reads emotional state from voice in real time rather than only transcribing words, and adapts tone and approach accordingly. Sage conducts inbound and outbound member calls covering health risk assessments, post discharge follow up, risk profiling, care gap closure, program enrollment, medication reminders, and triage, and is positioned explicitly as added staffing capacity rather than a chatbot, reserving clinicians for complex high touch interventions. Integrations include Salesforce Health Cloud and, through an April 2026 partnership with HealthEdge, the Care Solutions suite drawing on GuidingCare member data and returning outcomes to the platform. Company reported figures, which it acknowledges are not independently audited, include roughly 60 percent reduction in administrative tasks, 6x faster program enrollment, and 4x return on investment. Named customers per the company website include UnitedHealth Group, Aetna, Duke Health, and Highmark. Founded 2017 by CEO Mainul Mondal; approximately $75 million raised including a $45 million round in June 2025 co-led by Salesforce, Khosla Ventures, and CVS Health Ventures.

AI orchestration platform for provider side revenue cycle, founded 2022 and built around the payer relationship rather than internal workflow alone. The company frames itself as an autonomous intelligence overlay rather than a replacement system of record, continuously monitoring aged accounts receivable, commercial denials, and shifting payer behaviour. Two product lines work together: Adonis Intelligence provides detection, alerting, denial clustering, smart worklists, and analytics, while AI Agents execute, navigating third party payer portals to run real time medical necessity and authorization checks, extracting unstructured clinical notes from the EHR to draft and file appeal letters, and progressing claims to resolution. Reported automation covers more than 70 percent of standard claim statusing and appeals tracking routines with a stated 20 to 30 percent reduction in long term revenue cycle operating spend. Available through the Epic Connection Hub. Mount Sinai Health System is a named customer using the platform to identify and prioritize billing exceptions, and Fox Valley Orthopedics reported recovering nearly $200,000 in denials. The company publishes an annual State of Revenue Cycle Management benchmark report, whose 2026 edition found payer denials and reimbursement pressure had overtaken staffing as the primary threat to revenue performance. More than $95 million raised including a $40 million Series C in March 2026; co-founder and CEO Akash Magoon.

Oncology AI reading the full patient chart, founded 2021 on the observation that while software could already handle the roughly 20 percent of medical data that is structured, generative AI made the other 80 percent, the free text notes, tractable. OncoLLM is the underlying platform and the architecture is disclosed with unusual specificity: not one model but a constellation of eight specialized models ranging from 3 billion to 72 billion parameters, working agentically to interpret information at the patient level. Prism is the trial matching application, screening patients with upcoming appointments against all active trials and working in both directions, patient to trial and trial to patient, with continuous tracking. Matches are cited back to pathology, biomarkers, and note level evidence rather than returned as a bare recommendation. The platform has expanded beyond matching into verifiable patient summaries for visit preparation, cancer registry abstraction, and structured data generation for research. Reported results include a 40 percent increase in trial matches, more than 30 percent increase in enrollments, and 67 percent reduction in chart review time, with one NCI designated center reporting 100 percent screening coverage at three times the throughput of manual review. Peer reviewed validation has appeared in Nature Digital Medicine with presentation at ASCO, and a pilot study at the Medical College of Wisconsin Cancer Center covers gastrointestinal, genitourinary, breast, and thoracic teams. Mount Sinai Tisch Cancer Center deployed Prism in January 2026, becoming the first NCI designated Comprehensive Cancer Center in New York City to use it for systemwide matching. More than $36 million raised; co-founders Sarim Khan and Hrituraj Singh.

Generative AI for the provider side revenue cycle, formerly Alpha Health. Unified Automation is the platform: a single engine spanning coding, clinical documentation integrity, prior authorization, and claims, designed to sit on top of existing EHR systems rather than replace them. The architectural argument worth understanding is how it differs from robotic process automation. Rather than recording and replaying screen interactions, which break whenever a payer updates a portal, the company trains models on the behaviour of payer portals, EHR interfaces, and clearinghouse connections so they tolerate interface changes. Modules include Coding Optimizer surfacing missed CPT and ICD-10 codes and compliance risks, CDI Optimizer flagging ambiguous diagnoses and missing specificity, Authorization Advisor handling prior authorization submission and payer specific requirement matching, Auth Status and Claim Status polling payer portals and writing results back to the EHR. The company describes an expert in the loop design that autonomously handles high confidence encounters and escalates edge cases to revenue cycle staff. Models are reported as trained on more than 43 million clinical documents. Reported footprint spans more than 650 hospitals and 6,500 outpatient facilities across all 50 states, with a strategic collaboration with Cleveland Clinic announced to launch revenue cycle AI tools. Customer reported results include a 13 percent reduction in accounts receivable days and 300 or more staff hours saved monthly. Headquartered in South San Francisco; more than $200 million raised.

Note on naming: this is Artera of Los Altos, California (artera.ai), developer of multimodal AI cancer tests. It is unrelated to the separately indexed Artera of Santa Barbara (artera.io), which makes patient communication agents. The two companies share a name and nothing else. The ArteraAI Prostate Test is a multimodal artificial intelligence model combining digitized histopathology images from an existing biopsy with structured clinical data including age, PSA, and tumor stage, producing a continuous risk score from 0 to 1 with pre established cut points corresponding to roughly 3 percent and 10 percent estimated ten year risk of distant metastasis. It requires no additional procedure because it reads tissue already taken. Beyond prognosis it is predictive: for NCCN intermediate risk patients it estimates whether adding short term androgen deprivation therapy to radiation will reduce risk, which the literature describes as the first predictive biomarker for that decision. The algorithm is pre established and locked at version 1.2, developed from large datasets and multiple phase 3 randomized trials with up to 15 years of follow up. Regulatory and guideline standing is unusually complete: FDA De Novo marketing authorization in August 2025, inclusion in the NCCN Clinical Practice Guidelines for Prostate Cancer as the first and only AI risk stratification tool, and CMS coverage with a payment rate effective January 2024. In June 2026 the company introduced a digital pathology based test providing individual risk estimates in metastatic hormone sensitive prostate cancer. Co-founded by Felix Y. Feng of UCSF; CEO Andre Esteva.

AI digital pathology platform spanning human, veterinary, and environmental laboratories, developing in this field since 2013. Techcyte Fusion is positioned as the first digital workflow integrating anatomic and clinical pathology in one platform, with deep learning models identifying parasitic cells, bacteria, and cancer cells, plus digitization enabling remote case review. Product areas include parasitology, bacteriology, hematology with a peripheral blood smear classifier, cervical cytology, and bladder cancer surveillance. Regulatory status is the decisive buyer fact and the company states it plainly: the anatomic and clinical pathology platform and its human products are Research Use Only in the United States, while Fusion carries CE-IVDD marking in Europe. The architecture is deliberately open rather than proprietary, connecting to numerous slide scanners, laboratory information systems, and third party AI developers through a Fusion Partner Program; one such partner, Modella AI, brought its PathChat research copilot to the platform and was subsequently acquired by AstraZeneca in January 2026. A long running Mayo Clinic collaboration provides access to the Safe Harbour dataset of more than 17 million de-identified slides and pathology reports for model development. The company reports its veterinary segment is already profitable, with human and environmental segments targeted for profitability by 2027, and raised $15 million to expand the platform. Headquartered in Orem, Utah; CEO Ben Cahoon.

Health benefits navigation and care platform for self insured employers and health plans, indexed for its AI navigation layer with the surrounding care services as context. WayFinding is a generative AI experience launched in 2024 and scaled through 2025, combining benefits navigation, clinical guidance, and care access in one interface, delivering tailored recommendations from a member's own history so a member can determine what is covered, what it will cost, and where to go. Agentic capabilities were added in January 2026. The company completed a $621 million merger with Accolade in April 2025, taking the formerly NASDAQ listed company private and combining WayFinding and the Cancer Care, Surgery Care, Weight Health, and pharmacy benefit experiences with Accolade's health advocacy, expert medical opinion, virtual primary care, and its True Health Actions platform, which draws on employer data, health plan data, and electronic health records for targeted guidance. The combined organization reports serving more than 20 million members across more than 1,700 employer and health plan clients. Buyers should be clear that this is a hybrid: a substantial share of what is delivered is human advocacy, virtual clinical care, and second opinion services rather than AI. A $126 million Series D in May 2024 was raised specifically to build AI capability. Led by Glen Tullman.

Indexed for the AI capabilities inside the Doctolib platform rather than for the platform itself, which is context under this index's product scoping rule, and the first non US vendor treated this way. Doctolib is the dominant digital health infrastructure provider across France, Germany, and Italy, spanning appointment booking, practice management, and clinical records. Its ambient documentation capability, the Consultation Assistant, is built on technology from the June 2024 acquisition of Typeless, an EPFL and Idiap Research Institute spin off specializing in AI speech recognition, and uses large language models to convert spoken doctor patient dialogue into structured medical text including clinical notes and doctor letters. In November 2025 the company launched an all in one practice management product incorporating three AI assistants, including a telephone assistant that answers calls around the clock, categorizes inquiries, and transfers appointment bookings directly into the Doctolib system; the company reports practices can save up to ten hours per week on administrative tasks. That product launched for general practitioners, pediatricians, and gynecologists with additional specialties planned. The strategic significance is distribution: ambient documentation delivered inside the appointment and record workflow a practice already uses, which is a different competitive position from standalone scribes such as Nabla or Abridge. Note that European regulators treat ambient scribes as software as a medical device, with the UK MHRA classifying them accordingly, so regulatory posture differs from the US market.

AI clinical platform built for Latin America, and the first vendor in this index whose primary market is outside the United States and Europe. The platform combines ambient documentation, clinical decision support, and EHR integration: it transcribes consultations in real time and generates structured records adapted to each clinician's style, reviews the record, flags potential errors, and surfaces evidence based recommendations and institutional protocol guidance during the encounter. Models are trained on clinical guidelines, peer reviewed literature, and local institutional protocols, which is the substantive localization claim rather than translation alone. Since launching July 2025 the company reports deployment across more than 25 hospital systems in Brazil, Colombia, and Mexico, reaching 14 million patients and processing over 5 million consultations. Reported outcomes at customer sites include protocol adherence rising from 84 percent to 99 percent, physicians recovering roughly 1.7 to 2 hours daily, and 60,000 medical errors flagged in real time. Mater Dei in Brazil reports physicians using the platform around eight hours a day. A free tier targets independent private practice physicians who lack institutional technology access. The company positions the product as supporting clinicians rather than deciding, with the physician making the final call, and is operating while AI regulation is still forming regionally: Brazil's Senate has approved a risk based AI bill pending further approval, and Colombia has sent its own bill to Congress. Founded by Nicolas Abad after his father, a physician, died from a preventable drug interaction. $42 million raised including a $33 million Series A led by Andreessen Horowitz.

AI intelligence platform for life sciences medical affairs, scientific communications, and drug safety, which places it on the medical rather than commercial side of pharma and distinguishes it from vendors excluded from this index for pharmaceutical marketing. The Sorcero Intelligence Platform reads across a reported 263 million publications and 1.3 billion citations globally alongside congress sessions, reports, surveys, CRM interactions, safety cases, and medical inquiries, identifying which key opinion leaders and clinicians are active in specific research areas or treating relevant populations. Sorcero Medical serves medical affairs, with Field Medical Excellence and Insights including an iPad capture app and Congress Intelligence with scientific abstract integration, both introduced March 2026. Sorcero Safety, built with Springer Nature, covers literature and adverse event monitoring for pharmacovigilance. Sorcero MedTech came from the July 2025 acquisition of Axiom Health, extending the platform to medical device real world data and making it a unified platform across pharmaceutical and device organizations. The company describes a trust first approach with hallucination prevention and validated outputs, and an agentic architecture using specialized agents to validate medical information. Reported adoption is a third to 40 percent of the top 30 global pharmaceutical companies. Named a Leader in AI enabled pharmacovigilance software by CB Insights alongside IQVIA, Veeva, and Oracle. Six foundational medical AI patents; 2025 Google Cloud Partner of the Year for Healthcare and Life Sciences. $59 million raised in total including a $42.5 million Series B in November 2025. Co-founded and led by Dipanwita Das.

Inpatient virtual care platform, and the first vendor in this index covering AI assisted virtual nursing and virtual sitting inside the hospital rather than in the home. The platform is modular: AI Assisted Virtual Nursing supporting virtual rounding, admissions, and discharges; AI Assisted Virtual Sitting and Patient Safety Monitoring, where the AI models cover fall prevention, fall detection, and pressure injury prevention; plus ambient documentation, patient engagement, digital whiteboards and room signage, hospital at home, remote patient monitoring, and a digital clinic. Hardware is part of the offering, including smart carts and in wall fixed devices providing video in the patient room. The stated design intent is extending clinical capacity rather than replacing staff: continuous monitoring across multiple units simultaneously so a smaller number of nurses can observe more rooms and intervene earlier. Reported adoption grew from more than 70 US health systems in February 2026 to more than 100 by June 2026. Named enterprise deployments include Ardent Health (NYSE: ARDT) across more than 2,000 patient rooms, MultiCare Health System as its enterprise virtual care platform, and One Brooklyn Health. Headquartered in Clearwater, Florida.

Indexed for what is commercially available today, which requires care because the company's own AI algorithms are not yet cleared. MyoVista Insights is a cloud based ECG reporting and management platform, in phased rollout since May 2025 and shipping at version 1.3 as of June 2026, positioned to replace on premise ECG management software. Its AI-ECG Algorithm Marketplace, introduced in version 1.3, integrates third party algorithm results into the platform, and the first algorithm made available is Bunkerhill Health's FDA cleared ECG-EF model detecting reduced left ventricular ejection fraction at or below 40 percent from a routine 12-lead ECG. Bunkerhill is separately indexed here, so this is a distribution relationship between two vendors in this index rather than a HeartSciences algorithm. The company's own pipeline is not yet available: the MyoVista wavECG device, a 12-lead resting ECG built to host AI-ECG algorithms, was submitted for 510(k) clearance in December 2025 and clearance was not confirmed at the time of this record; its impaired cardiac relaxation algorithm was deliberately separated from that submission to complete additional validation against revised American Society of Echocardiography guidelines for diastolic dysfunction; and its low ejection fraction algorithm remains in pre submission work. Underlying intellectual property is licensed in part from the Icahn School of Medicine at Mount Sinai. Assistive AI-ECG assessments are eligible for Medicare reimbursement under the Hospital Outpatient Prospective Payment System at APC 5734. NASDAQ: HSCS.

Payment accuracy and integrity for health plans, and the oldest company in this index by founding date: it began in 1989 and its pre payment editing engine is the former ClaimsXten, with over 30 years of rules and policy content behind it. That history matters to the AI question, because the machine learning sits on top of an established rules engine rather than replacing it. Lyric42 is the orchestration platform, coordinating payment decisions across rules, workflows, policy, and payment accuracy products, and designed to let a plan run a multi vendor strategy through one integration to core systems. Replay is the audit automation engine, using AI to prioritize high impact claims and automate DRG validation, coordination of benefits review, and itemized bill analysis, with the company reporting up to 3x productivity and 4x findings for internal audit teams while reducing dependence on external vendors. LyricIQ provides the analytics layer. The stated framing is decision intelligence producing payment decisions that are independent, verified, and explainable, applied before disputes and rework enter the system. Named 2025 Best in KLAS for Pre payment Accuracy and Integrity, and reports serving more than 100 payers. Headquartered in Newtown Square, Pennsylvania.

Patient financial experience platform for hospitals, health systems, and physician groups, covering the part of revenue cycle the patient actually experiences: the bill. Cedar Intelligence is the AI decision engine personalizing billing journeys across channels, and Kora is the voice agent, launched April 2025 and developed with Twilio, trained on the company's proprietary billing data rather than a general model. Kora resolves common billing inquiries on first contact, explaining charges, identifying payment options, and connecting patients to financial assistance, with sentiment and tone detection, multiple language support including Spanish, and escalation to a live agent with full context when human judgment is required. One year in, the company reports Kora has handled nearly 400,000 patient calls across ten provider organizations spanning Epic and Cerner health systems, physician staffing groups, and large specialty groups, with Gastro Health alone accounting for more than 60,000 calls since September 2025. Kora Outbound extends the agent to proactive engagement of harder to reach patients. The company reports its platform data foundation exceeds one billion patient interactions. Its own published research is unusually pointed for a vendor: 40 percent of collectible dollars on its platform now come from uninsured patients, up 54 percent in three years, and it argues that billing experiences designed for financially stable patients are failing those under the greatest strain.

Infrastructure for building medical imaging AI rather than a clinical application, which makes it structurally different from every other vendor in this lane. Grace is a multimodal foundation model supporting image to image and text to image learning across X-ray, CT, MRI, and echocardiography, trained on over a petabyte of permission based anonymized imaging studies enriched with corresponding reports across 2D, 3D, and longitudinal series. The HOPPR AI Foundry is the surrounding development environment, combining accelerated computing, curated datasets, foundation models, fine tuning tooling, and traceable development workflows inside a stated HIPAA compliant environment, so developers, radiology PACS vendors, and AI companies can build, evaluate, fine tune, validate, and host imaging models without assembling that infrastructure themselves. NVIDIA open models NV-Reason and NV-Generate became available on the Foundry in March 2026, with NV-Reason generating structured analytical reasoning alongside outputs. The MC Chest Radiography Narrative Model, introduced April 2026, is a vision language model translating chest X-rays into structured descriptive text, shipped with training data traceability records and version locking so developers can reproduce results. Forward Deployed Services pairs HOPPR machine learning staff with customer teams for fine tuning. Founded 2019, led by Dr Khan Siddiqui; $34.5 million raised including a $31.5 million Series A in June 2025, with Health2047, the American Medical Association venture studio, among investors.

Audio based AI monitoring for home care and senior living, and the third distinct sensing architecture in this lane. Small audio pods placed through a residence listen for verbal and non verbal cues rather than using cameras, a deliberate choice the founder attributes to cameras feeling intrusive in the home. The Care Agent continuously detects and predicts care events across physical, cognitive, and emotional wellbeing, and the company reports identifying more than 100 distinct insights, extending well past emergencies: alongside falls it flags possible urinary tract infections, pneumonia, early signs of cognitive decline, and softer signals including changes in activity level, sentiment, and lack of companionship. A clinical team including a social worker, occupational therapist, nurses, and geriatrics clinicians develops new data points on an ongoing basis. The platform has expanded beyond monitoring into agency operations with a Growth Agent handling inbound demand and an Ops Agent covering scheduling, callouts, and communication. The company reports serving 80 percent of the largest home care networks in North America and revenue tripling year over year for three consecutive years. Founded 2019 by Romi Gubes; $45 million Series C in October 2025 led by Qumra Capital brought total funding above $98 million.

AI utilization management, and the only vendor in this index positioned to sit between payer and provider rather than serving one side. The Dragonfly platform (formerly CORTEX) uses real time predictive analytics to continuously assign an objective medical necessity score, the proprietary Care Level Score, and an anticipated level of care for every patient, with the stated intent of removing subjectivity from patient status determination so both parties work from the same evidence. Product lines cover Utilize for utilization review and case management, Navigate for discharge readiness and length of stay, Advise for physician advisor workflow and peer to peer escalation, and revenue integrity for denials and appeals. Precision UM is the deepest tier, a shared utilization management approach between a health system and a health plan built on common clinical data and historical determination patterns. Integration with the EMR is bidirectional. The company also sells Physician Advisor Services, supplementing night and weekend coverage or operating fully outsourced, so buyers should separate the platform from the staffed service. Named outcome: AnMed reported 14.6x return on investment over a twelve month period and 1,221 hours of front end review time saved through Precision UM with a national health plan. A third party study found Dragonfly rendered clinical review determinations 38 percent faster than fax and 15 percent faster than through the EMR. Headquartered in Franklin, Tennessee; co-founded by Joan Butters.

Indexed for the AI platform and agent portfolio rather than for the wider clinical research services, data, and consulting business, which is context under this index's product scoping rule. IQVIA (NYSE: IQV) launched IQVIA.ai in March 2026, a unified agentic platform and agent marketplace spanning clinical, commercial, and real world operations, built on the company's proprietary health data and Healthcare grade AI together with NVIDIA Nemotron, NeMo Agent Toolkit, Dynamo, and LangChain, following a collaboration begun over a year earlier. Disclosed agent use cases include target identification, clinical data review, literature review, market assessment, and healthcare professional engagement. The company reports filing more than 100 AI related patents and deploying more than 150 intelligent agents across internal teams and client environments, with 19 of the top 20 pharmaceutical companies having begun incorporating IQVIA agents into their workflows. IQVIA AI Assistant is a generative interface over the company's existing solutions and data products. The commercial side of the portfolio includes healthcare professional targeting and engagement, which sits closer to pharmaceutical marketing than to clinical operations and should be evaluated separately from the research and clinical agents.

Health data interoperability API with an AI enrichment layer on top. The base capability is retrieval: a single bidirectional API querying national health information networks including CommonWell, Carequality, and eHealth Exchange plus ADT feeds and prescription data, reaching a reported 320 million patient records across more than 70,000 healthcare organizations, with the company stating it locates roughly 90 percent of patients nationally. The Particle Insights Platform is where the AI sits, built on three stated pillars: enhanced data quality through parsing that surfaces critical elements, enrichment by integrating additional sources, and usability through normalization and deduplication. Snapshot applies AI powered summarization to condense retrieved records, and the company has built an AI discharge summary product. Its published engineering writing is unusually candid about the underlying problem, describing why template based CCDA parsing loses clinically important medications and why identity resolution rather than event delivery is the real failure mode in discharge alerting. Buyers are health technology companies, telehealth and remote monitoring vendors, care management organizations, and payers rather than provider organizations directly.

Indexed for the AI capabilities inside the Veeva Vault platform rather than for the platform itself, which is context under this index's product scoping rule. Veeva (NYSE: VEEV) is the dominant software platform for life sciences, spanning clinical, regulatory, safety, quality, medical, and commercial, with customers including Novo Nordisk, Gilead, Bristol Myers Squibb, Merck, Roche, Moderna, and BioMarin. Veeva AI Agents became available in December 2025, initially for Vault CRM (Free Text Agent flagging issues in call notes, Voice Agent for spoken input, Pre-call Agent assembling context) and PromoMats (Quick Check Agent scanning promotional content against brand and regulatory guidelines before medical, legal, and regulatory review, and Content Agent assisting reviewers). Agents are built on large language models from providers including Anthropic and Amazon, hosted on Amazon Bedrock but operating inside the Vault environment, accessible through the Vault interface or API and customizable through Veeva's AI framework. Safety and quality agents are reported live, with clinical and regulatory agents tied to the 26R2 release. Availability matters here and is stated rather than blurred: two further announced product lines are not yet available. Falcon, a separate platform for standardized agentic labor covering trial master file intake, safety case processing, and health authority interaction management, targets late 2026 for early adopters, and Agentic Authoring, which drafts submissible regulatory documents, is expected in late 2027. Neither is indexed as a shipping capability.

Indexed for the AI capabilities layered across the Medidata clinical trial platform rather than for the platform itself, which is treated as context under this index's product scoping rule. A Dassault Systemes brand, the underlying platform spans more than 38,000 trials and 12 million patients across roughly 2,300 customers and over one million registered users, anchored by Rave EDC. The AI products indexed here: Clinical Data Studio, an AI data quality management workspace that integrates Medidata and non Medidata sources, identifies data issues and safety signals, and is reported by one named customer to deliver up to 80 percent faster data review; Medidata AI Study Build within Designer, which automates study construction; and an AI imaging capability introduced at ASCO 2026 using proprietary algorithms including automated text detection that the company reports makes protected health information redaction 32 percent faster. Health Record Connect uses FHIR and health information exchanges to pull patient health records into trial data capture, reducing manual re entry at sites. The company reports its AI has supported more than 500 clinical studies over a decade, with more than 120 AI supported studies starting in 2025. Named customers for the AI products include Eisai.

AI platform for clinical data management and trial operations, sold to pharmaceutical and biotech sponsors. The Life Science Analytics Cloud is reported in use across more than 1,500 studies at over 50 pharma and biotech companies, and the company states its platform supported the trial behind the first COVID-19 vaccine. Core modules include Data Hub for harmonizing trial and real world data, Smart Data Quality which automates data review and query generation, Patient Insights, and Source to Submission which auto generates regulatory submission artifacts. An embedded generative AI co pilot writes and tests the code for cross domain data quality checks, removing manual programming from trial setup. In September 2025 the company introduced modular Clinical AI Agents built on its Agentic AI Framework, spanning study start to submission and designed explicitly to operate on partial autonomy with human oversight and controls, capable of independent reasoning, planning, and execution. Reported model depth is over 90 to 100 specialized models trained on life sciences data. Customer reported results with Pfizer include query handling time reduced by roughly 90 percent, data transformation time by roughly 50 percent, and submission timelines by roughly 35 percent. Named AI based Life Sciences Solution of the Year in the 2026 AI Breakthrough Awards, a third such recognition. Received a strategic growth investment of up to $430 million led by Carlyle with Amgen Ventures, Merck Global Health Innovation, McKesson Ventures, Pfizer Ventures, and Northpond participating.

Prior authorization decision support for health plans and pharmacy benefit managers, the third payer side vendor in this index alongside Cohere Health and Alaffia, and the one weighted toward pharmacy benefit rather than medical. BanjoPA automates the end to end workflow: the CARE engine extracts information from faxed or digital prior authorization requests, validates and maps it to case fields, then matches the case against the payer's own clinical criteria. The distinguishing technical step is that CARE transforms dense clinical guidelines into decision trees, converting narrative coverage policy into an executable structure, and the platform reads prescriber notes directly from the EHR rather than relying on manual data entry or fax and phone follow up. The company states its model matches each request against the specific payer's rules rather than applying generic AI, and that every AI generated recommendation carries detailed evidence and an explanation. BanjoA&G extends the same approach to appeals and grievances. Positioned around CMS-0057-F interoperability and prior authorization compliance. Holds HITRUST r2 certification. Named implementation with Navitus, a large transparent pass through PBM owned by SSM Health and Costco serving over 18 million lives, expanded across employer and health plan lines including Medicare and Medicaid in December 2025. Founded by Saar Mahna.

Real world evidence generation, spun out of Stanford's Green Button project in 2020 and built to answer the question a clinician actually has at the bedside when no trial covers their specific patient. GENEVA OS is the underlying operating system across a federated network the company describes as exceeding 300 million anonymized patient records. ChatRWD is a chat based application that generates publication grade observational studies in minutes rather than months, without requiring a data scientist in the loop, and Green Button remains as a consultation service delivering evidence within 48 hours. Alexandria is the company's evidence library of pre computed evidence briefs. Two design decisions distinguish it: ChatRWD is an LLM independent framework, so an institution can maintain its own model security posture, and every answer carries a Real World Fitness Score rating how fit for purpose the underlying dataset was for that specific question, which is an explicit and unusual admission that evidence quality varies by question. Stanford Health Care has moved from using the service to embedding it in physician workflow and clinical notes. The Atropos Evidence Agent is distributed via the Databricks Marketplace under a partnership announced June 2025.

Healthcare data and agentic AI platform, described by the company as an agentic cloud for healthcare, built in three stages: data connectivity integrating Epic, Cerner, MEDITECH, and Allscripts with payer claims, pharmacy, lab, remote monitoring, and social determinants sources across a reported 80 million plus patient records; applications on top of that data; and now autonomous agents. Gravity is the underlying data platform, continuously trained on real world healthcare data including claims denials and edge cases, which the company argues gives each new agent institutional context at launch. Sara is the AI assistant line spanning insights, care management, and clinical documentation via Sara Scribe. A suite of pretrained voice enabled agents covers appointment scheduling, protocol intake, referral management, routine patient inquiries, prior authorization, care gap closure, hierarchical condition category coding, and transitional care management, supporting clinicians, care managers, risk coders, patient navigators, and contact center staff. The stated architectural claim is end to end workflow connection: a prior authorization agent can hand off to coding and denial management agents rather than each operating in isolation. Reports serving six of the top 10 US health systems and more than 130 healthcare organizations, with named customers including Kaiser Permanente, Ascension, and Trinity Health. Best in KLAS recognition across data and analytics, population health management, and CRM categories. Founded 2014; $675 million raised in total including a $275 million Series F, with investors including Kaiser Permanente and Banner Health.

Conversational AI agent platform built for healthcare since inception rather than adapted to it, spanning call centers, websites, SMS, and mobile apps. The architecture is deliberately hybrid: large language models combined with a proprietary conversational engine, small language models tuned for healthcare, and knowledge graphs purpose built for the domain, which the company positions as more controllable than a general model alone. Agents integrate through API into EHRs and CRMs to complete tasks autonomously, including registration, routing, scheduling, and prescription refills, with contextual transfer to a live human when needed, and all interactions captured in a Patient Intelligence Dashboard. The company reports resolving up to 85 percent of routine patient interactions, deployment across more than 45 to 50 US health systems, and over 30 million patients engaging with its agents. Named clients include Intermountain Health, Baptist Health, Hackensack Meridian Health, and Bon Secours Mercy Health, which also invested. Founded 2018 by Israel Krush and Rom Cohen as a Cornell Tech spinout with offices in New York and Tel Aviv; $95 million raised in total including a $45 million round in October 2025 led by Healthier Capital with ServiceNow Ventures participating. Named to Fierce Healthcare's Fierce 15 for 2026.

AI fall detection and prevention for senior living, with a center of gravity in memory care. Wall mounted devices in resident rooms use computer vision to detect falls in real time and alert staff, capturing a short event based video rather than a continuous livestream, so care teams can review what actually happened and address root cause. The company cites that 95 percent of falls are unwitnessed and that residents with cognitive impairment often cannot recount them, which is the specific gap the video review closes: at one operator the system identified nearly 200 silent falls where a resident self recovered and never reported it. The platform spans Safety AI for detection, Guardian hardware including sensors, pendants, and buttons, Discover as the staff web portal, Insight for clinical consultation, and Halo, launched 2025, which merges detection with next generation emergency call and adds virtual check ins, ambient care tracking, and staffing analytics. Reported reach is more than 800 communities over seven years. Note the architectural contrast with Inspiren, also indexed here: SafelyYou uses cameras with event based capture, while Inspiren uses camera free skeletal imaging. Both address the same problem with materially different privacy tradeoffs. More than $70 million raised across Series A and B, with early NIA Small Business Innovation Research grants totaling over $2.8 million.

Clinical intelligence platform sold to health plans, spanning utilization management, payment integrity, appeals, care management, and policy management. The company states it is sold to health plans, and that providers and manufacturers do not license the platform, which makes it payer side alongside Alaffia. Cohere Unify combines a reported 350 or more clinically trained AI models with workflow automation and human review to auto determine prior authorization requests in real time, and Cohere Connect provides the prior authorization APIs, reported to have carried more than 15 million submissions and to support 47 million payer provider interactions annually. The critical design fact is the direction of automation: the company reports up to 85 percent real time approvals and states explicitly that remaining submissions are reviewed by a clinician before final determination, meaning the model approves and humans decide the rest. Additional products include Cohere Review Assist for acute inpatient care, Cohere Policy Studio, and a Payment Integrity Suite extended through the September 2025 acquisition of ZignaAI. Reported outcomes include care access 70 percent faster than traditional processes, up to 9x return on investment, 94 percent provider satisfaction, and a provider NPS of 67. Named plan relationships include Humana and Geisinger. $90 million Series C in May 2025.

AI agent platform for healthcare operations, spanning patient access, revenue cycle, and care operations rather than a single workflow. Agents automate patient intake and registration, appointment scheduling, insurance eligibility verification, prior authorization, denial management, patient payment estimates, referral processing, and post visit follow up, each running a defined workflow end to end. Flow Builder is a no code interface that lets an organization's own IT and non technical staff build, train, and deploy agents, which places it alongside Bunkerhill and XCaliber as a build your own platform rather than a fixed product set. Integration is unusually pragmatic and is the stated differentiator: the company uses whichever method reaches the field, including APIs, RPA, and HL7, reading and writing structured and unstructured data across Epic, Oracle Health, MEDITECH, athenahealth, and payer portals. Named health system deployments include Intermountain, Trinity Health, and MUSC. Published customer results include a health system reaching 64 percent voice containment with roughly $360,000 annual savings, and an insurance FAQ voice assistant answering all inbound calls at a stated $4 saving per call. Backed by Greylock and ICONIQ Growth.

Agentic patient services platform for pharmaceutical manufacturers, automating the post prescription access journey that determines whether a prescribed therapy ever reaches the patient. Named agents handle distinct functions: a consent agent manages opt in for sharing patient health information across manufacturers, specialty pharmacies, and provider hubs; a marketing agent personalizes educational outreach from multi source data; and an enrollment agent accelerates virtual hub enrollment by automating document verification, form completion, and payer navigation around the clock. Ships modular pre configured solutions including automated annual reverification, digital enrollment, bridge to copay sweeps, and click to agent conversational interfaces. The company positions itself as an alternative to traditional labor intensive hub models, where enrollment and reverification are handled by large human teams. Formerly Lifelink Systems, founded 2015; Precision AQ made a strategic investment in 2025 and named an incoming chief executive.

Multi agent platform automating clinical and administrative workflows from a single interface, with a coordinated network of role specific agents: an AI Receptionist handling inbound and outbound calls, scheduling, and patient communication; an AI Medical Assistant running intake, triage, and history capture; an AI Scribe producing real time documentation with ICD-10 and CPT evidence links; AI Coder and Biller agents for coding and revenue cycle; and an AI Inbox Manager working refills, messages, labs, and follow ups. States bidirectional integration with Epic, Cerner, and Allscripts and HIPAA compliance, with paperless intake syncing to the EHR. Marketed on reduced clinical support staff cost and shorter patient wait times, with stated attention to rural and underserved providers. Founded 2023 in Bellevue, Washington; emerged from stealth in late 2025 with a seed round. Early stage, and the breadth of the agent roster should be weighed against how recently the company began selling.

Hub of conversational AI agents for hospitals, operating across three orchestrated layers: triggers, where agents identify clinical gaps and risks from health assessments, prescriptions, and diagnostic findings; navigation, where agents qualify patients and guide care journeys; and revenue, where pending care is converted into booked services. Patients calling or messaging reach conversational AI with no menu and no IVR, and the agent accesses the real schedule to resolve the request end to end. After a visit an agent reads the medical record, identifies prescribed exams and consultations that were never booked, and proactively offers scheduling over WhatsApp, recapturing care that would otherwise be lost to follow up. Other agents confirm appointments with preparation guidance to reduce no shows. WhatsApp as the primary channel reflects the market: the company serves reference hospitals in Brazil and Mexico and is scaling across Latin America, which makes it one of the few vendors in this index built for a non US care and communication context. Pre seed stage; founded by Sergio Ricardo Santos.

Clinician led transitional care focused on the high risk window after hospital discharge, sold to health systems and payors as a clinical service line rather than as software alone. The proprietary clinical AI, AiME, was built by clinicians and grounded in physician validated protocols: it engages patients in real time, interprets symptoms against the individual's medical history, medications, and comorbidities, continuously detects emerging risk signals, and escalates to a dedicated Transitionist, a licensed clinician who owns the episode of care from discharge through recovery. The model pairs an AI front door with a physician led practice, adding AI assisted care plans, documentation, and billing plus omnichannel round the clock patient support. The company is credited with large reductions in avoidable readmissions. As with several vendors in this category, buyers should evaluate the AI and the care delivery operation as two distinct things: what is being purchased is a staffed clinical service accelerated by AI, not a platform. Founded 2023; $13.5 million Series A in March 2026 led by Team8 and Table Management, bringing total funding to nearly $20 million.

AI native revenue operations platform for post acute care providers including home health, hospice, home care, and nursing homes, a segment the larger revenue cycle vendors largely do not serve. Automates the referral to reimbursement cycle across revenue assurance, smart intake, authorization autopilot, billing operations, and platform intelligence. The model identifies upstream data, documentation, and coverage risk inside the EMR to prevent denials before submission, centralizes and auto extracts referrals arriving by fax, email, and portal, automates prior authorizations from submission through renewal, and resolves claims to cash through posting, reconciliation, and prioritized denial follow up. Routine work is automated while exceptions surface to human billers who make the decisions. Voice agents for insurer information requests are in development. Founded 2025 by Kevin Calcado and JJ Ram; $4.4 million seed in January 2026 led by Maverick Ventures with Peak XV, Y Combinator, and executives at large post acute providers participating.

AI native operating system for behavioral health clinics, combining a set of named AI workers with an integrated EHR, CRM, and revenue cycle management in one platform. Sarah, the admissions coordinator, answers inbound calls, texts, and faxes around the clock and verifies insurance in real time, with more than 100,000 patients booked reported. Emma, the clinical assistant, generates ICD-10 and CPT coded session notes within about 30 seconds and is reported to have supported more than 3 million patient sessions. Eric handles coding, claim scrubbing, submission, and denial management. Laura manages between visit engagement. The fully integrated platform launched April 2026, partners with athenahealth through the athenaOne Marketplace, and reports clinics booking 30 percent more patients with clinicians saving more than two hours daily, across hundreds of mid to large behavioral health clinics. Behavioral health operations are a distinct problem from general practice, and the specialization is the point. Backed by Y Combinator, Precursor Ventures, Pioneer Fund, Rebel Fund, and Expansion Venture Capital.

Clinical AI platform built around Almanac Copilot, which the company describes as a Level 1 autonomous EHR agent: it retrieves and summarizes patient data, drafts notes, places orders, and surfaces prioritized alerts, dynamically selecting and chaining tools from a defined set including FHIR functions, a browser, clinical calculators, a Python interpreter, and the EHR database. As a Level 1 agent it acts only on explicit clinician command and requires review and approval of every action. Grounded in peer reviewed evidence in a vector database rather than an unconstrained model, and stated to be free of pharmaceutical advertising, a deliberate contrast with ad supported clinical reference products. On the EHR QA benchmark of 300 common EHR tasks it reported a 74 percent completion rate, matching much larger models. Founded by physician researcher Cyril Zakka MD, whose Stanford work introducing retrieval augmented generation to clinical medicine became one of NEJM AI's most cited papers. Important scope note carried from the source record: the company characterizes the platform as validated through research rather than shipped as a finished product, and it is undergoing clinical validation in academic medical center settings. $10 million seed in April 2026 led by F-Prime with General Catalyst and Lightspeed.

AI revenue integrity platform for specialty physician practices, surgery centers, and health systems, working both sides of the denial problem. To prevent denials it reviews every encounter against coding standards, payer policy, and the practice's own contracts, checking CPT, ICD-10, HCPCS, modifiers, NCCI edits, and documentation completeness, returning suggested corrections that carry the underlying rule and its source from CMS, NCCI, or payer policy rather than an unexplained flag. To recover them it identifies root cause, retrieves records, references payer policy and contract terms, drafts the appeal packet with clinical evidence, and tracks it through adjudication. Also provides ambient scribing across dozens of specialties, benchmarks payer rates to surface underpayments, and tracks payer policy changes. Runs on US based cloud infrastructure stated as HIPAA and SOC 2 compliant. Reports 55 to 57 percent fewer denials and 98 percent coding accuracy for customers. Co founded by a former healthcare AI product manager at Google and a CTO with explainable AI research background at MIT CSAIL; $4.3 million seed in November 2025 led by Nexus Venture Partners with Y Combinator.

AI billing and revenue cycle management for dental practices, combining automation with in house billing staff. Connects directly to practice management systems including Open Dental, automating insurance verification with full benefit breakdowns, clean claim submission with attachments, payment posting within 24 hours, denial appeals using payer specific templates, and accounts receivable follow up tracking claims aging past 30, 60, and 90 days. The distinctive capability is an AI voice agent that calls payers directly when a resubmitted claim shows no update, navigating the phone tree and updating claim status automatically, the same payer facing pattern Prosper AI applies on the medical side. The vendor reports maintaining current contract data across more than 50 major payers, enabling automated eligibility without manual contract uploads. Founded 2023 by Shreyas Parab and Anton Lin; seed stage with AI Grant among investors.

Agentic operating system positioned as a coordination layer across the systems a provider already runs rather than a replacement for them, on the premise that health systems accumulated EHRs, billing platforms, and scheduling tools over two decades without ever acquiring a layer to coordinate between them. Merlin is the role based agent line, and Patient Navigator, the first shipped agent, spans scheduling, prescription refills, outreach, intake, referrals, prior authorization, and billing resolution. The architecture is deliberately semi autonomous: agents run routine administrative workflows end to end and act across silos in real time, while a human in the loop structure keeps teams in control of critical decisions, with the degree of autonomy varying by whether a task is operational or clinical. The platform blends generative AI with traditional machine learning and microservices so deterministic tasks stay deterministic. Reports processing more than 8 million chart updates and generating over 160,000 EHR updates daily across more than 700,000 unique patients, with the navigator agent saving providers an average of six hours of manual work per day on refills alone. EHR integrations include Epic, Cerner, athenahealth, and eClinicalWorks, with listings on the athenahealth and AVIA marketplaces. Led by co founder and CEO Prakash Khot, previously a co founder of Skyflow; $6.5 million seed announced May 2026. Headquarters is reported as Andover, Massachusetts in funding announcements and as Plano, Texas by Crunchbase; this record does not resolve the discrepancy.

Tech bio company combining biological large language models, multimodal patient data, and agentic software. The Owkin K co pilot has two environments: K Navigator, an agentic research environment free to academic researchers that accelerates literature review across 26.5 million articles and 19 biomedical databases and explores spatial multiomic patient data, and K Pro, an enterprise co pilot that uses a single orchestrator to select and combine specialized biological AI skills across drug discovery and development. Both are powered by Owkin Zero, a fine tuned biological reasoning model. The company reports K Pro accelerating internal drug target identification from more than 12 months to roughly 3 months, validated through collaborations with AstraZeneca, Bristol Myers Squibb, and Sanofi, including a three year AstraZeneca licensing agreement to build biopharma agents. Owkin operates a group of entities spanning a biology foundation model (Bioptimus), diagnostics (Waiv), and a clinical stage drug program (Epkin); this record covers the software platform. Founded 2016 by Thomas Clozel, MD and Gilles Wainrib, PhD.

Agentic AI for health plan claims operations, and the only payer side vendor in this lane: the buyer is the plan rather than the provider. Covers the full claims lifecycle across payment integrity, utilization management, and appeals. Proprietary optical character recognition digitizes unstructured itemized bills and medical records, agents extract and structure clinical facts and cross reference a claim against the complete patient record, clinical criteria, and policy guidelines, automating routine cases and prioritizing high value claims for human review. A generative assistant helps reviewers summarize records, source guidelines, and draft determination responses. The company states it deliberately avoids black box denial algorithms: every recommendation carries a clinical rationale and traceable citations, and licensed clinicians validate and sign off. Maintains SOC 2 Type II, HIPAA, and HITRUST. Reports saving health plans more than $120 million, over 20 percent average savings on high cost facility claims, and go live in roughly 30 days. Founded 2020 by siblings TJ Ademiluyi and Adun Akanni; $55 million Series B in February 2026 led by Transformation Capital, bringing total funding above $73 million.

Specialty depth ambient scribe, built for complex specialty medicine rather than general primary care, with oncology as its center of gravity: the company reports 5 million oncology visits captured a year and roughly 40 percent of US cancer care visits documented on the platform, alongside tuned models for cardiology, urology, gastroenterology, orthopedics, neurology, and nephrology. Holds a 98.8 KLAS Emerging Company Spotlight score with A+ marks across all six measured categories, the highest independent rating in the category, plus 2025 KLAS Top 5 rankings for improving outcomes, patient experience, and clinician experience. Positioned as an Ambient Operating System rather than a scribe: bidirectional integration with Epic, athenahealth, NextGen, and eClinicalWorks reads chart context before the visit and writes structured data into discrete fields after, pulling prior notes, labs, imaging, medications, and diagnoses forward into the current note. AI coding builds HCC, CPT, and ICD-10 suggestions into the note, SmartPrep adds pre visit intelligence for oncology, and Customization Studio learns each clinician's documentation style. Conversations supported in more than 110 languages. Founded 2017.

Self serve ambient scribe positioned against the enterprise vendors in the lane: a clinician can sign up and be generating notes the same day with no sales call, no IT deployment, and no annual contract. Reports more than 25,000 clinicians across over 1,000 organizations and more than 32 million patient visits transcribed. Records on phone, desktop, or tablet and returns a structured SOAP note within a minute or two. Pricing is fully published, which is rare in this category. The tradeoffs are stated plainly by third party review: EHR Push works through a Chrome extension into browser based EHRs with no native API write back, so structured field level integration is out of scope, and specialty depth outside primary care is a known weakness with procedure heavy documentation needing more editing. Security posture is strong for the tier, including SOC 2 Type II, a HIPAA Business Associate Agreement by default, automatic deletion of recordings, and an opt out from model training. Community health center Camarena Health deployed across 55 clinicians and 24 sites without formal implementation. Founded 2022.

Clinical AI platform pairing ambient scribing with evidence grounded clinical reasoning, which the other scribes do not attempt. Clinicians describe a case in natural language and the platform returns a ranked differential with suggested workups, drafts a problem oriented assessment and plan with inline evidence links, and answers clinical questions with citations drawn from an index of more than 38 million peer reviewed articles, consensus guidelines, and FDA information covering over 154,000 drug compounds. In the Harvard and Stanford ARISE NOHARM evaluation, a physician validated clinical safety benchmark, the platform ranked among the top medical AI systems. The scribing side produces clinic notes, H&P notes, progress notes, discharge summaries, and patient handouts, with assisted EHR workflows across Epic, eClinicalWorks, athenahealth, and Elation. A Developer API exposes the full stack, including clinical question answering, chart summarization, differential generation, care planning, and scribing, so other platforms can embed the clinical intelligence. Independent testing notes reasoning is strongest on common presentations and weaker on complex multi system cases, and the company positions the product as decision support requiring physician judgment on every output. Founded 2021 by Dr Dereck Paul and Graham Ramsey.

Voice first clinical assistant pairing ambient documentation with an interactive command layer over the EHR, which is what separates it from passive scribes. Clinicians can dictate, capture visits ambiently, or issue voice commands to order medications, navigate charts, query patient records, stage orders for review, and pull schedules. The product also handles ICD-10, E/M, and HCC coding assistance, chart aware clinical questions answered against the specific patient record, and pre visit summaries, with reported volume of roughly 125,000 consults per week. EHR reach is a core strength: deep bidirectional integrations with Epic, Oracle Health, athenahealth, MEDITECH, and Elation, plus an EHR Partnership Program extending to MEDENT, Azalea Health, and WellSky. Suki Platform, launched 2024, lets other healthcare software vendors embed the voice and ambient capabilities inside their own products. Audio and transcripts are deleted after 30 days by default. Founded 2017 by Punit Soni.

AI models of tumor and immune biology applied to precision oncology, serving both clinical care and drug development. The Tumor Portrait test integrates DNA and RNA exome sequencing into a single end to end assay, approved under CLIA, CAP, and the New York State Department of Health, producing tumor driver, microenvironment, and actionable biomarker characterization from one sample. Kassandra is the company's cell deconvolution model for reconstructing tumor microenvironment composition. Clinical and analytical validation was published in Communications Medicine, part of the Nature portfolio, across more than 2,200 tumors, reporting high reproducibility and clinical actionability in 98 percent of cases. Research collaborations span MD Anderson Cancer Center, Weill Cornell Medicine, and the Parker Institute for Cancer Immunotherapy, with nine abstracts accepted at ASCO 2026, and biopharma partnerships include Takeda for trial design and biomarker signature identification. A Japan joint venture operates with NEC Corporation and Japan Industrial Partners.

AI care platform sold to self insured employers and health plans, indexed for those business to business products rather than the direct to consumer application launched in 2026, which is outside the scope of this record. Phoenix, the company's AI care specialist, delivers real time motion biofeedback and around the clock natural language support, paired with a licensed clinician who remains in the loop for every member: Doctors of Physical Therapy in the musculoskeletal programs, with specialist type varying by product. Thrive covers musculoskeletal care through digital physical therapy with a motion tracking device, and the line has extended into women's health (Bloom) and cardiometabolic care (Pulse, announced for later 2026 with outcomes based pricing and connected device integration). The company reports more than 800,000 members served, 11 million AI care sessions, over 1,000 clients including a fifth of the Fortune 500, and customer avoided costs exceeding $1 billion, alongside per member savings of $3,177 a year for the musculoskeletal program. Founded 2015 by Virgilio Bento; valued at $3 billion following a 2024 round led by Khosla Ventures and General Catalyst.

Rare disease genomic diagnosis (NASDAQ: WGS), applying AI and expert variant interpretation to exome and genome sequencing. GeneDx Infinity is the company's rare disease genomic dataset, accumulated over roughly 25 years and described by the company as the largest and most comprehensive of its kind. Products span ExomeDx and GenomeDx, both granted FDA Breakthrough Device designation, ultraRapid genome sequencing returning results for NICU and PICU patients in as little as 48 hours, and GenomeDx Prenatal, a phenotype informed trio based whole genome test for pregnancies with fetal anomalies. The company is the sole commercial testing provider for the NIH BEACONS genomic newborn screening initiative, which aims to enroll up to 30,000 newborns across as many as ten states. Reimbursement position is unusually well documented: Medicaid coverage for exome or genome sequencing in the pediatric outpatient setting across 38 states and for rapid genome sequencing in the NICU across 17. Full year 2025 revenue of $427.5 million with 2026 guidance of $475 to $490 million.

AI for gastroenterology across two product lines. SKOUT is a real time computer aided polyp detection device that received FDA 510(k) clearance in 2022 for adults undergoing colorectal cancer screening or surveillance, applying computer vision to endoscopic video to flag suspicious tissue during the procedure. In a randomized controlled trial published in Gastroenterology, SKOUT demonstrated a 27 percent relative increase in adenomas detected per colonoscopy, and the company states it was evaluated in the largest US based multicenter clinical study completed for a computer aided detection device in this category. The vendor reports the device does not extend total procedure or withdrawal time. Distribution runs through an exclusive partnership with Provation, a GI documentation vendor reporting more than 3,500 customer facilities. The second line, Clinical Trial Optimization and AI Recruitment, applies machine learning to endoscopic image scoring and patient identification for inflammatory bowel disease trials, serving life sciences sponsors rather than providers.

Indexed for the AltitudeAI product suite rather than for the underlying revenue cycle platform, which is treated as context under this index's product scoping rule. AltitudeAI, launched January 2025, brings the company's AI capabilities under one brand across a cloud based RCM platform serving a reported one million providers and processing more than six billion transactions annually, reaching roughly half of US patients. AltitudeCreate applies generative AI to autonomously draft appeal letters for denied claims, drawing on a library of more than 1,100 payer specific appeal templates. AltitudePredict uses predictive analytics to score and prioritize denied claims by expected cash value and likelihood of being overturned. AltitudeAssist, in Claim Manager, converts user prompts into automated denial prevention recommendations that fix issues before submission, which the company reports compresses a three day process to roughly three minutes. The company reports early AltitudeAI results of appeal package creation three times faster, saving about 16 minutes per package. Publicly traded (NASDAQ: WAY).

Ambient AI scribe generating structured clinical notes in real time from in person or telehealth encounters, reported across more than 85,000 clinicians at over 150 health organizations, weighted toward hospital systems, emergency departments, and multi provider groups. Two characteristics distinguish it. The first is EHR breadth: integrations span Epic, athenahealth, Oracle Health, NextGen, and Greenway, one of the widest footprints in the category and a practical fit for organizations running mixed EHR environments. The second is language coverage across roughly 31 languages, with templates spanning more than 35 specialties customized through custom instructions and dot phrases. The vendor reports that about 55 percent of users save at least an hour a day on documentation with a 27 percent reduction in burnout, figures it attributes to a published NEJM study. Two disclosures matter for procurement and are covered in the capability records: the free tier reportedly does not include a Business Associate Agreement, and session data is used for model training by default. Founded 2018 in Paris.

Real world data company built on records patients choose to contribute, indexed for the life sciences data platform rather than the free consumer application, which is the collection mechanism rather than the product sold. Patients use a free app and web platform to aggregate their records from more than 50,000 US healthcare providers across Epic, Oracle Health, athenahealth, Quest, and the VA, then consent to contribute de identified data for research. Novellia's AI stitches those fragmented sources into structured longitudinal patient journeys spanning a reported 15 to 20 years, which the company positions against conventional real world data assembled by brokers from claims and partial hospital records. Buyers are biopharma teams in HEOR, market access, clinical operations, and medical affairs; the company reports customers among a majority of the top 10 to 15 global pharmaceutical companies. Raised an $18 million Series A led by Spark Capital in June 2026, bringing total funding to $28 million. Founded by Shashi Shankar, previously at Genentech working on real world data.

Housing stability platform sold to health plans and employers, addressing housing instability as a driver of avoidable medical utilization. The model is explicitly hybrid and the company describes it as human led and AI accelerated: licensed social workers and housing specialists called Care Guides deliver the intervention, supported by proprietary AI for acuity stratification, case summarization, and predictive housing matching against a curated database of public and non public affordable housing inventory. The company states it deliberately avoids general purpose language models in favor of a purpose built social determinants matching framework. Serves Medicaid, Medicare Advantage, D-SNP, commercial, and employer sponsored populations across the full continuum from crisis intervention to long term tenancy support, and reports partnerships with more than 17 national, regional, and state health plans across 10 states including four of the largest US payers, with a named Medicaid housing supports contract from UnitedHealthcare of New Jersey. Reported results include more than half of enrolled members stabilized within 90 days. Founded 2020; raised a $20 million Series A in June 2026 led by Aquiline with Flare Capital Partners.

AI care platform for senior living operators, combining proprietary hardware with software. AUGi is a discreet wall mounted device that monitors resident rooms without cameras, using skeletal imaging the company calls geometric exoskeletal monitoring to detect falls, identify hazards, and track movement and behavior patterns while preserving privacy. AUGi Call adds an emergency call system with two way voice and privacy protected live visual context for triage. Inspiren HQ aggregates the device data into clinical and operational dashboards covering care level accuracy, staffing, and incident replay. The company reports that data driven care level accuracy has recovered up to 30 percent of revenue otherwise missed through under assessed care levels, and a ten month study with Solera Senior Living at its Lumina Las Vegas memory care community reported a 48 percent reduction in resident falls and a 54 percent drop in hospitalizations. Each community is assigned a dedicated clinical specialist. Raised a $35 million Series A led by Avenir.

AI marketplace for permanent healthcare hiring that inverts the application model: employers apply to nurses rather than the reverse. A predictive matching engine screens credentials and preferences against algorithms recognizing more than 70 specialties and 250 skills, generative AI processes resumes and drafts tailored recruiter outreach, and two AI agents extend the platform, Gale as a career partner handling resume building and mock interviews, alongside Lyn. The vendor reports 1.5 million US healthcare workers and 1,500 healthcare employers on the platform, permanent roles filled in under 20 days against industry averages several times longer, a 20 percent increase in interview request acceptance after introducing generative outreach, and 15 percent higher retention for nurses hired through the platform. Free to nurses and paid by employers. Founded 2017 by Dr Iman Abuzeid; roughly $100 million raised at a reported $1.65 billion valuation.

Precision oncology company (NASDAQ: CAI) combining comprehensive molecular profiling with AI interpretation. MI Cancer Seek received FDA approval in November 2024 and is, per the company, the first and only assay performing simultaneous whole exome and whole transcriptome sequencing with FDA approved companion diagnostic indications for solid tumors, analyzing more than 23,000 genes from a single tissue sample for adult and pediatric patients. The CodeAI platform runs over a large multimodal clinico genomic dataset to generate Caris AI Insights, a set of proprietary signatures predicting therapy response, tissue of origin, and metastasis risk, delivered in the Caris Molecular Tumor Board Report. Signatures added through 2026 include brain metastasis risk in breast and lung cancer, trained on 12,994 NSCLC and 3,371 breast cancer cases with matched survival outcomes. MI Clarity applies AI and computational pathology to stratify breast cancer recurrence risk without genomic sequencing. Caris Assure is the blood based platform. Went public in June 2025 raising $494 million; biopharma partners include a large alliance with Merck KGaA.

Patient communications platform with AI virtual agents across voice, text, and web, formerly WELL Health. Not to be confused with ArteraAI, a separate prostate cancer AI company at artera.ai. The Harmony platform coordinates agentic AI across the patient journey with staff able to take over at any point and full conversation history retained, covering self scheduling, intake, forms, referrals, and billing questions. Flows Agents apply natural language understanding to automate multi step patient conversations, and AI Co-Pilots assist staff with translation, message shortening, and conversation summaries. The company reports more than 1,000 provider organizations including specialty groups, federally qualified health centers, large IDNs, and federal agencies, roughly 2 billion communications annually across 109 languages, and engagement with 100 million patients a year. Artera Government Solutions serves the Department of Veterans Affairs, Department of Defense, and Indian Health Service sites. In May 2026 the company introduced an AI services model pairing the platform with its own build teams. Raised a $65 million growth round in December 2025.

Clinical AI for imaging triage, delivered through aiOS, an enterprise AI operating system that handles data normalization, continuous performance monitoring, and governance so health systems can run multi condition AI without re architecting infrastructure. In January 2026 the FDA cleared what the company describes as healthcare's first comprehensive AI triage solution, powered by CARE (Clinical AI Reasoning Engine), its self developed foundation model. The clearance brought 11 newly cleared indications together with three previously cleared into a single abdomen CT workflow, 14 in total, and per the FDA reviewed pivotal study the new indications reported a mean sensitivity of 97 percent and mean specificity of 98 percent, with the company reporting roughly an order of magnitude reduction in false alerts against single condition tools. The company reports more than 100 million patient cases analyzed on aiOS. A successor model, CARE2, has been announced, and a multi year collaboration with Amazon Web Services supports the foundation model work. Co founded and led by Elad Walach.

Indexed for the AI products embedded in Elation's primary care platform, not for the electronic health record itself, which is treated as context under this index's product scoping rule. Note Assist is an ambient scribe that transcribes the visit and structures it into the clinician's own note templates natively inside the chart rather than as a bolt on. Actions listens for clinical intent within the note and drafts the resulting work, including prescriptions, lab orders, and referrals. Clinical Insights surfaces conditions, labs, and medications as a contextual summary at the point of care. AI Fast Lane, launched March 2026, applies Smart Coding to suggest diagnosis and procedure codes from the visit note and problem list, routing claims above a confidence threshold straight to submission without manual review. The commercially material fact for buyers is that Elation states its native AI is included at no additional cost with the EHR subscription. The company was named top solution for Small Practice Ambulatory EMR/PM for 1 to 10 physicians in 2026 Best in KLAS, a recognition covering the platform rather than the AI. Founded 2010 by Kyna Fong and her brother.

AI documentation suite pairing an ambient scribe with point of care automation modules, positioned as an operating system rather than a note taker. AutoScribe produces a fully structured note in about twenty seconds, classifying statements into documentation sections with specialty tuned models covering more than 200 specialties including emergency and hospital medicine. The surrounding suite is what distinguishes it: AutoCDI validates notes against ICD-10 and CPT requirements at the point of care with audit trails for revenue cycle teams, AutoAVS generates patient friendly after visit summaries in the patient's language, AutoRefer drafts referral letters, and AutoPrep reads prior charts to prepare a visit agenda. A Chart Awareness platform launched February 2026 grounds notes in the full longitudinal record including prior notes, labs, imaging, medications, and problem lists. Native API integrations with Epic, Oracle Health, and athenahealth. Cleveland Clinic selected Ambience over four rival scribes for a five year deployment; also reported at UCSF, Memorial Hermann, John Muir Health, The Oncology Institute, and GI Alliance. Support is English first, which points the product at large health systems rather than independent practices.

Enterprise ambient AI documentation platform that turns the clinician patient conversation into a structured, billable note inside the EHR. Named Best in KLAS for Ambient AI in both 2025 and 2026, and reported in use at more than 250 health systems including Kaiser Permanente across roughly 25,000 physicians, Mayo Clinic, Johns Hopkins, Duke Health, UPMC, and the VA. The defining technical strength is Epic depth: embedded across Haiku, Canto, and Hyperdrive with bidirectional note sync, plus an athenahealth partnership, covering more than 28 languages and 55+ specialties across outpatient, inpatient, and emergency settings. Linked Evidence maps every part of a generated note back to the source audio so a clinician can verify any sentence against what was actually said before signing. The platform has extended into structured orders, coding context for revenue cycle, and real time prior authorization through a collaboration with Highmark Health and Allegheny Health Network. Founded 2018 by Shiv Rao, a practicing cardiologist, and Zachary Lipton of Carnegie Mellon.

Enterprise genomics platform for health systems, payers, and life sciences. Health systems run population genomics programs on Helix infrastructure, covering recruitment, clinically actionable disease screening, return of results, and research, built on the proprietary Exome+ assay and a CLIA certified, CAP accredited sequencing lab. The Helix Research Network spans roughly 20 health system members and a reported 400,000+ sequenced participants, feeding GenoSphere, a linked clinico-genomic dataset that passed 500,000 records in June 2026, each combining Exome+ sequencing with an average of 13 years of EHR history and 8 years of claims. AI tooling is a recent layer rather than the foundation: an AI Cohort Builder launched June 2026 and a Model Context Protocol connector for querying the dataset launched July 2026. Health system programs include Cone Health, Sanford Health, WellSpan, St. Luke's University Health Network, HealthPartners, Nebraska Medicine, and Memorial Hermann.

Automates HIPAA Expert Determination, the statistical de-identification standard that governs whether a health dataset can lawfully be used for analytics, research, or model training. The platform detects and remediates PHI entities in structured and unstructured data, assesses re-identification risk, and produces a signed determination opinion from qualified statisticians, an approach the company describes as expert in the middle: automated analysis with human certifier sign off. Unlike Safe Harbor, which strips 18 fixed identifiers, Expert Determination is scoped per dataset and preserves more analytic utility. For AI training corpora the platform replaces real PHI with synthetic entities rather than redacting, so text remains natural for model training. Deploys inside the customer's VPC, on premises, or air gapped environment as container images. Originated in healthcare and is extending the same methodology to financial, consumer, and AI training data, which buyers should weigh when assessing healthcare specific depth.

Clinical trial technology platform combining decentralized trial execution and electronic clinical outcome assessment with an agentic AI layer added in 2026. Agent Studio is a no code agent builder the company describes as the first agentic AI platform purpose built for clinical development, letting sponsor teams configure agents for protocol development, trial planning, and data workflows, with human in the loop validation and integration across life sciences systems. Shipped agents include TMF Agent for trial master file document management, announced January 2026, and a Digital Data Flow Agent that converts trial protocols into machine readable data. The underlying platform is reported deployed in nearly 400 trials across 70 countries and 120 languages, serving more than one million patients, and was named a Leader in eCOA by Everest Group. Founded 2014; CEO and cofounder Dr Michelle Longmire.

AI voice agents for patient access and revenue cycle telephony. The distinguishing capability is direction: alongside patient facing calls for scheduling, intake, and billing questions, the agents call payers directly, navigating IVR trees, waiting on hold, and speaking with representatives to obtain benefits and prior authorization details when electronic eligibility transactions return incomplete data, then writing structured results back to the EHR or practice management system. Every call is automatically reviewed by AI for accuracy and compliance rather than by manual audit. The vendor reports reaching more than 150,000 healthcare providers and cites roughly three week implementation. Founded 2023; raised a $30 million Series A led by Andreessen Horowitz in 2026, following a $5 million seed.

AI platform that retrieves, aggregates, and structures fragmented medical records into longitudinal patient histories, originally built for oncology and since extended to all therapeutic areas. The Clinical Clarity Engine applies natural language processing and machine learning to unstructured records; the company reports processing more than 300 million medical records from over 550,000 healthcare locations, with every structured output linked back to its source document. The xDECIDE provider portal presents structured data, autogenerated summaries, and AI assisted treatment option reports with scientific rationale, ranked by the xCORE engine and reviewed through a virtual tumor board; xINFORM is the patient facing portal. Data products supply longitudinal real world oncology datasets to research and regulatory programs. Holds HITRUST e1 certification. Raised a $46 million Series B in June 2026.

Generative AI for radiology reporting and follow up. Omni Impressions generates a report impression from the radiologist's dictated findings, learning each radiologist's language preferences from their historical reports. Omni Reporting auto fills structured templates from natural dictation, and Omni Unchanged pulls stable findings forward from prior reports, which the vendor reports cuts follow up dictation time by half using up to 90 percent fewer words. Continuity tracks incidental findings through to completed follow up; the vendor reports health systems using it improved follow up exam completion from roughly 30 percent to over 75 percent. Works inside existing PACS, RIS, and EHR systems. Series C reached $68 million including strategic investments from four health systems.

AI platform for inbound healthcare document and referral operations. RaeLM, the company's proprietary vision language model, reads unstructured inbound material including faxes, scanned forms, and handwritten documents, extracts the clinical and administrative data, and evaluates it against payer criteria to flag likely denials before submission. The vendor reports RaeLM was trained on more than 100 million anonymized healthcare documents, 2.3 billion data fields, and 8,000 sets of payer criteria, and that the platform processes more than 10 million documents a month for over 150 healthcare organizations. Tennr Network gives referring providers, receiving providers, and patients shared referral status visibility. Voice AI for referral phone workflows was added in 2026. Raised $162 million total, including a $101 million Series C led by IVP in June 2025 at a $605 million valuation.

Precision health technology company, indexed here for its business to business products rather than its consumer app. Lightpath is an AI enabled chronic care management program sold to health plans, employers, and pharmacy benefit managers, using agents to triage and escalate members to a clinical team of physicians, pharmacists, and dietitians, with Lightpath Metabolic covering diabetes, prediabetes, and obesity. Workbench is a research data environment used by the NIH All of Us Research Program, the Michael J. Fox Foundation, and Helix. Sightline is a wastewater based epidemiology program for early infectious disease detection. The free Verily Me consumer application is outside the scope of this record. Formerly an Alphabet subsidiary; became an independent company in March 2026 alongside a $300 million investment round.

No code AI workflow automation for pharmacy and healthcare operations, with a center of gravity in 340B program compliance. The platform screens 340B eligible claims, uses language models to investigate unstructured EHR data for referral based savings, and automates rebate reporting, Maximum Fair Price reconciliation, intake, and prior authorization. Referral Agent, launched June 2026, is positioned by the company as the first AI agent purpose built for 340B referral capture. The vendor reports customers including Tampa General Hospital, Renown Health, and Salinas Valley Health, more than 100 healthcare organizations on the platform, and customer reported reductions in manual work of up to 97 percent. Founded by Joy Liu, previously an operator at a health system specialty pharmacy company. Raised a $50 million Series B in 2025.

Dental AI for radiographic pathology detection. Not to be confused with Pearl Health, a separate company in value based care intelligence also indexed here. Second Opinion analyzes bitewing, periapical, and panoramic radiographs in real time at chairside, highlighting up to 18 findings per image including caries, bone loss, calculus, periapical radiolucencies, and defective restoration margins. Second Opinion 3D extends the platform to CBCT, making Pearl, per the company, the first dental AI company with FDA clearance for both 2D and 3D radiologic analysis. Additional clearances cover pediatric caries detection from age four and AI segmentation. The panoramic clearance was supported by a standalone performance study and a fully crossed multi reader multi case study. The company reports regulatory clearance in 120 countries and a published study in which operator diagnostic accuracy rose from 82 percent to 98 percent with the tool. Founded 2019 by Ophir Tanz.

Blood based early cancer detection built on a multiomics platform that analyzes genomic, epigenomic, and proteomic biomarkers and applies machine learning classifiers to detect cancer signals in circulating tumor DNA at single base methylation resolution. SimpleScreen CRC, the colorectal screening test, has a Premarket Approval application under FDA review submitted August 2025, with the company anticipating a decision in 2026; it is not FDA approved. The pivotal PREEMPT CRC validation study was published in JAMA in 2025, and blood based testing was included in the American Cancer Society's updated colorectal screening guideline in 2026. An updated assay version reported 85 percent sensitivity for colorectal cancer and 22 percent for advanced precancerous lesions at 90 percent specificity in a 966 sample head to head validation. Under an exclusive license agreement, Exact Sciences holds US commercial rights, and a separate commercial collaboration with Abbott covers bringing the test to market.

Global ambient AI scribe that generates structured clinical notes from the patient encounter, with the broadest language coverage in the category. The vendor reports more than 2.5 million consults a week across 110 languages, 190 countries, and over 200 specialties. The product has expanded beyond documentation: Heidi Evidence (launched February 2026) surfaces cited clinical decision support from BMJ, NICE, and HealthPathways at the point of care, and Heidi Comms coordinates patient calls. Pricing is published, which is rare in this category. Founded in Melbourne by Dr Thomas Kelly, a former vascular surgical resident; raised a $65 million Series B in October 2025 led by Point72 Private Investments.

Deep learning software that enhances and accelerates medical image acquisition on existing scanners rather than detecting pathology. SubtlePET (FDA cleared 2018) and SubtleMR (2019) denoise and sharpen PET and MRI images, allowing faster and lower dose acquisition; SubtleHD (MR) cleared November 2025 and SubtleHD (PET) cleared May 2026 extend that with newer model architectures, with SubtleHD (PET) supporting all FDA approved radiotracers and, per the vendor, up to 75 percent faster PET imaging. A CT product has clearance pending. The company reports 11 FDA clearances, more than 25 peer reviewed publications, and deployment on more than 1,300 scanners, with customers including Mount Sinai, RadNet, and Radiology Partners. Raised $33 million in growth capital anchored by a Series C led by Morgan Stanley Expansion Capital in 2026.

AI foundation models for molecular design, licensed as software to pharmaceutical and life sciences R&D organizations. The models predict and reprogram interactions between biochemical molecules: Chai-1 (2024) for structure prediction, Chai-2 (2025) for fully de novo antibody design, and Chai-3 (2026), which the company describes as roughly doubling the success rate of its predecessor. On Chai-2, the company reports designing all complementarity determining regions from a target and epitope prompt alone, with hit rates reported between roughly 16 and 20 percent depending on the source, against sub 0.1 percent rates the company attributes to prior methods; validation covered approximately 50 antibody targets with fewer than 20 designs tested per target. Models are reported in production at Eli Lilly, Pfizer, and Novartis, with a collaboration announced with argenx. Unlike vendors that use AI to build their own drug pipeline, Chai's product is the model itself, including custom versions trained on a customer's proprietary data.

Agentic AI platform for health systems. Carebricks lets clinical and operational teams build, deploy, and govern their own AI agents across clinical, operational, and administrative workflows rather than buying a point solution per use case. Agents in production include coronary calcium detection on routine chest CT, nephrology triage, lung nodule follow up, referral prioritization, prior authorization packet assembly, and registry automation. The company develops its own FDA cleared imaging algorithms that run inside the platform, including algorithms for coronary artery calcium and aortic valve calcium on contrast enhanced non gated chest CT, mitral annular calcification, and bone mineral density. CMS established a national billing code and OPPS payment for algorithmic CAC and AVC analysis on chest CT effective April 1, 2026. In production at Cleveland Clinic, the University of Texas Medical Branch, Intermountain Health, and Mayo Clinic. Founded by Nishith Khandwala, previously a researcher at Stanford's Center for Artificial Intelligence in Medicine and Imaging.

Generative AI drug discovery company (HKEX: 3696) operating both as a platform vendor and a clinical stage biotech. Pharma.AI comprises PandaOmics (AI target identification and indication prioritization), Chemistry42 (generative molecular design using generative tensorial reinforcement learning rather than library screening), and inClinico (clinical trial outcome prediction). The platform's flagship validation is rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis where AI selected the target, generated the molecule, and informed trial design: it entered a 320 patient Phase III trial in July 2026, with discovery published in Nature Biotechnology and Phase IIa results in Nature Medicine. The vendor reports reaching preclinical candidate nomination in 12 to 18 months on average against a 2.5 to 4 year industry norm, and 13 programs cleared for IND.

AI clinical trial matching and enrollment platform for oncology. SYNERGY-AI extracts structured information from patient records including biomarker data and matches against a reported 19,000+ active oncology and hematology trials, with matches audited by certified oncology case managers before use. The platform includes physician and patient facing assistants and a trial enrollment orchestration layer (TrialRelay). Peer reviewed evidence is unusually strong for this category: a prospective evaluation in 3,804 metastatic cancer patients published in ESMO Real World Data and Digital Oncology reported matching four times faster than conventional methods using a neuro symbolic, multi agent architecture with an oncology specific knowledge graph. Reports 200,000+ onboarded patients and customers spanning pharma, CROs, and community oncology practices.

Lung cancer diagnostics company (NASDAQ: BIAF). CyPath Lung is a noninvasive test for early stage lung cancer that combines flow cytometry of a patient sputum sample with automated analysis developed by machine learning, using a fluorescent porphyrin preferentially taken up by cancer and cancer related cells. Per the company's SEC filings, AI standardizes sample data analysis and patient test results. Physicians order the test to assess patients with small indeterminate pulmonary nodules. In a clinical trial of high risk patients with nodules under 20 millimeters, the company reports 92 percent sensitivity, 87 percent specificity, 88 percent accuracy, and 99 percent negative predictive value. Marketed as a laboratory developed test through the company's own CLIA laboratory and explicitly not intended as a sole diagnostic tool.

Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing with machine learning to detect a cancer signal from a blood draw and predict the tissue of origin. Reported to detect signals across more than 50 cancer types. The evidence base is unusually deep for this index: PATHFINDER 2 enrolled 25,490 participants and the NHS-Galleri trial enrolled more than 140,000 asymptomatic participants in England, the only prospective randomized controlled trial of a multi cancer early detection test for population screening. GRAIL submitted the final module of its FDA Premarket Approval application for Galleri in January 2026; the test carries FDA Breakthrough Device designation (2018) and is currently offered as a laboratory developed test.

Home care technology and operations platform for aging care. Honor licenses the Honor Care Platform to independently owned home care agencies (the Honor Care Network) and, since its 2021 acquisition of Home Instead, owns the world's largest home care franchise network. The AI does caregiver to client matching and scheduling: the CEO has stated more than 20 distinct AI algorithms run in the Home Instead network, modeling caregiver motivations across many dimensions to fill shifts and improve retention. This record covers the B2B platform licensed to agencies, not the consumer facing care service.

Global mental health platform for employers and health plans. The AI core is Precision Mental Healthcare: machine learning models analyze large data sets to match members to the right care modality and provider, with Compass, the company's mental health specific EHR, capturing every provider patient interaction and feeding measurement based care insights back to providers. Serves 800+ companies. Recovery outcomes were reported in a peer reviewed JAMA Network Open study (average time to remission 5.9 weeks, roughly 70 percent of participants reliably improved). The company published VERA-MH, a responsible AI framework for mental health. Buyer is the employer or health plan rather than the provider organization; indexed here on the standalone index where behavioral health is in scope.

Cloud native genomics analysis company (NASDAQ: SOPH). The SOPHiA DDM platform applies machine learning with patented algorithms to call, annotate, and pre classify variants from next generation sequencing data, technology agnostic across sequencing instruments, with genomics, radiomics, and multimodal analytics modules. Deployed as software that hospitals and labs run themselves: at Mount Sinai, for example, SOPHiA provides the analytical software while the health system runs it as a laboratory developed test in its own CLIA certified, CAP accredited lab. The platform reports a network of more than 750 hospitals, academic centers, and labs and a federated learning model across participating institutions. Certain applications are research use only and regional clearance varies.

Healthcare cybersecurity platform, delivered as Medigate by Claroty (also positioned as Claroty xDome for Healthcare). Purpose built to discover, profile, and protect connected medical devices (IoMT), IoT, and building management systems on hospital networks, using passive deep packet inspection and light active techniques across a reported 500+ device protocols, with an Advanced Anomaly Threat Detection module that adds clinical context to prioritize threats. Protects a reported 20 million plus devices across 2,000+ hospital facilities and has been named Best in KLAS for Healthcare IoT Security multiple years. Claroty acquired Medigate in 2022.

Precision medicine company (NASDAQ: TEM) whose provider software is what this index covers: Next, an AI clinical decision support system that alerts clinicians to patients who may have fallen off care guidelines, backed by a vendor reported 662 patient prospective study across six sites; Hub, a physician platform rebuilt on an agentic architecture including a prior authorization agent; and David, a generative AI clinical assistant deployed directly into the EHR, with Northwestern Medicine as the first health system. Tempus acquired Deep 6 AI in March 2025, adding a precision research platform that applies natural language processing to structured and unstructured EMR data to match patients to clinical trials in near real time and to generate real world evidence. Deep 6 reports real time EMR feeds across more than 30 health systems, an ecosystem of over 1,000 research facilities including 18 academic medical centers and 11 NCI designated cancer centers, and that sites find more than 25 percent more patients than with traditional recruitment; the company notes 92 percent of trial inclusion and exclusion criteria benefit from unstructured data and that 15 to 20 percent of eligible patients are found through unstructured data alone. Outputs are positioned as decision support requiring trial team validation before action. The sequencing and pharma services businesses are context, not indexed products.

Value based care enablement platform for Medicare providers: AI powered predictive insights identify the highest urgency patients so care teams intervene before costs escalate, alongside financial risk modeling and workflow automation for scheduling and post discharge follow up. Supports more than 10,000 providers across 40+ states serving roughly 250,000 Medicare beneficiaries, with about $3.6 billion in annualized medical spend under management. Raised $110 million in July 2026 ($50 million equity led by Andreessen Horowitz plus a $60 million credit facility). Pearl is a hybrid: predictive software wrapped in risk bearing value based care enablement, and this record covers the platform.

Conversational AI for healthcare operations, indexed here for the HealthAI product line: voice, text, email, and chat agents that handle patient scheduling, reminders, refills, billing questions, and intake, booking directly into the EHR and handing off to staff when needed. The vendor reports 95 percent of patient inquiries handled without human intervention, support for more than 50 languages, and HIPAA and SOC 2 Type II compliance. The company's property management business is out of scope for this index.

AI powered healthcare workforce training platform operating as school as a service for health systems: employer sponsored, debt free training pathways for medical assistants, pharmacy technicians, practical nurses, dental assistants, and surgical technicians, expanding into registered nursing, respiratory therapy, and imaging. AI runs through instruction (personalized learning), avatar based clinical simulations, remote skills assessment, and workforce planning. Reports more than 32,000 graduates and 35+ health system clients including Mount Sinai, Ochsner, and Providence. Raised a $55 million Series C led by Oak HC/FT in June 2026, bringing total funding to $105 million.

General Catalyst backed roll up of Athelas, Augmedix, and Memora Health selling ambient clinical documentation that flows directly into autonomous coding, clinical documentation integrity, and claims automation. The ambient line spans Augmedix Go (AI drafted notes), Assist (AI plus specialist review), and Live (synchronous human documentation), integrates with more than 50 EHRs including Epic, Oracle Health, and MEDITECH, and is reported to power more than 250,000 providers. A January 2025 Vizient contract provides negotiated access for member health systems.

Safety focused patient facing voice agents for non diagnostic clinical work: post discharge follow up, medication adherence, preoperative instructions, chronic care check ins, and screening outreach, conducted by voice and text in more than 20 languages. Built on the Polaris constellation architecture, in which specialist support agents for privacy, checklists, and medication safety back the primary conversation agent and can end a non compliant conversation. Agents are barred from diagnosis and prescribing, escalate to humans when clinical judgment is required, and pass a certification pipeline that includes simulated call testing by thousands of nurses and physicians. More than 300 prebuilt agents across 25 specialties; the company reports over 115 million clinical patient interactions and 50 plus health system, payer, and pharma partners.

AI medical search and clinical decision support used at the point of care, free to verified United States clinicians and monetized through pharmaceutical advertising, with enterprise health system deployments embedding the platform in the EHR. The company reports more than 757,000 verified physician users and use by more than 40 percent of practicing US physicians, with enterprise per seat contracts emerging alongside the free tier.

AI enabled chronic care management for older adults: supervised AI agents monitor daily vitals from connected devices, surface risk between visits, and coordinate clinical action for patients with hypertension, type 2 diabetes, heart failure, and COPD. Operates in partnership with more than 20 health systems with an embedded medical group, and reports 55 percent of vitals alerts resolved autonomously with a 3.5 minute median response time.

Specialty specific AI voice agents for the patient journey: scheduling, intake, triage and routing, referrals, medication refills, document processing, and payments, writing directly to the EHR in real time across more than 20 systems including native Epic and athenahealth integration. The platform is marketed as Assort OS, built on the Synapse proprietary model and trained on a reported 62,000 care protocols and 1.6 million decision pathways across more than 22 specialties. Patient interaction volume is vendor reported and varies across the company's own materials, cited as 180 million on its Crunchbase profile and 190 million elsewhere; trade coverage in October 2025 cited 42 million, so the figure is growing and should be read as directional. Agents include configurable stop logic that triggers a warm handoff when identity cannot be confirmed, required details are missing, or a patient signals clinical urgency.